ORENCIA (abatacept) Injection

DESCRIPTION

ORENCIA® (abatacept) is a selective T cell costimulatory modulator. ORENCIA is a soluble fusion protein consisting of the extracellular domain of human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and a modified Fc (hinge, CH2 and CH3 domain) of human immunoglobulin G1 (IgG1). . Abatacept is produced in mammalian cell expression systems through recombinant DNA technology. The apparent molecular weight of abatacept is 92 kilodaltons.

ORENCIA injection is a lyophilized powder for intravenous infusion. ORENCIA injection is a sterile, white, preservative-free lyophilized powder that can be reconstituted and diluted before intravenous administration. After reconstituting the lyophilized powder with 10 mL of sterile water for injection (USP), the ORENCIA solution is clear, colorless to light yellow, and the pH is 7.2 to 7.8. Each single-use ORENCIA injection bottle provides 250 mg abatacept, maltose (500 mg), sodium dihydrogen phosphate (17.2 mg) and sodium chloride (14.6 mg) for administration.

ORENCIA injection is a sterile, preservative-free, transparent to slightly milky white, colorless to light yellow solution, and the pH range for subcutaneous administration is 6.8 to 7.4. named patient program ORENCIA injections are available as single-dose pre-filled syringes or single-dose ClickJect auto-injectors

EMPLICITI INDICATIONS

EMPLICITI is indicated in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies. EMPLICITI is indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.

DOSAGE AND ADMINISTRATION

Recommended Dosing When EMPLICITI Is Used In Combination With Lenalidomide And Dexamethasone

The recommended dosage of EMPLICITI is 10 mg/kg administered intravenously every week for the first two cycles (28-day cycle) and every 2 weeks thereafter in conjunction with the recommended dosing of lenalidomide and low-dose dexamethasone as described below. Continue treatment until disease progression or unacceptable toxicity.

Refer to the dexamethasone and lenalidomide prescribing information for additional information. Administer premedications before each dose of EMPLICITI [see Premedication and WARNINGS AND PRECAUTIONS].

Administer dexamethasone as follows:

On days that EMPLICITI is administered, Pharmaceutical Consulting Company give dexamethasone 28 mg orally between 3 and 24 hours before EMPLICITI plus 8 mg intravenously between 45 and 90 minutes before EMPLICITI. On days that EMPLICITI is not administered but a dose of dexamethasone is scheduled (Days 8 and 22 of cycle 3 and all subsequent cycles), give 40 mg orally.
 

EMPLICITI ( Uses, Doses, Side effects )

Elotuzumab is a humanized recombinant monoclonal antibody directed against SLAMF7, a cell surface glycoprotein. Elotuzumab consists of the complementarity determining region (CDR) of the mouse antibody MuLuc63, which is grafted onto the framework of the human IgG1 heavy chain and kappa light chain. Elotuzumab is produced in NS0 cells by recombinant DNA technology. The theoretical mass of the intact antibody of Eclozumab is 148.1 kDa.

EMPLICITI (Elocizumab) is a sterile, pyrogen-free, preservative-free lyophilized powder that is white to off-white in a single-dose vial, whole or fragmented cakes. EMPLICITI for injection is provided at the price of 300 mg per bottle and 400 mg per bottle, and needs to be formulated with sterile water for injection USP (13 mL and 17 mL, respectively) to obtain a solution with a concentration of 25 mg/mL. After reconstitution, each vial contains excess filling to allow 12 mL (300 mg) and 16 mL (400 mg) to be pumped. named patient program, The reconstituted solution is colorless to slightly yellow, transparent to slightly opalescent. Before intravenous infusion, dilute the reconstituted solution with 0.9% Sodium Chloride Injection USP or 5% Dextrose Injection USP [see Dosage and Usage].

Each EMPLICITI 300 mg single-dose vial also contains the following inactive ingredients: citric acid monohydrate (2.44 mg), polysorbate 80 (3.4 mg), sodium citrate (16.6 mg) and sucrose (510 mg).

Each EMPLICITI 400 mg single-dose vial also contains the following inactive ingredients: citric acid monohydrate (3.17 mg), polysorbate 80 (4.4 mg), sodium citrate (21.5 mg) and sucrose (660 mg).

ICLUSIG Precautions

 Before taking ponatinib, tell your doctor or pharmacist if you are allergic to it; or if you have other allergic reactions. This product may contain inactive ingredients, which may cause allergic reactions or other problems. Contact your pharmacist for more details.

Before using this medication, please tell your doctor or pharmacist your medical history, especially: liver disease, heart disease (such as history of heart attack, angina pectoris, hypertension), previous stroke or "stroke" (transient Ischemic attack)), diabetes, high cholesterol, smoking.

This medicine may make you dizzy or blurred vision. Alcohol or marijuana (cannabis) can make you dizzy. Before you can operate safely, do not drive, use machinery, or perform any operations that require vigilance or clear vision. Limit alcoholic beverages. If you use marijuana (marijuana), consult your doctor.

Before proceeding with surgery, please inform your doctor or dentist of all the products you use (including prescription drugs, over-the-counter drugs and herbal products).

Do not get immunizations without the consent of your doctor. named patient sales Avoid contact with people who have recently received live vaccines (for example, flu vaccine inhaled through the nose).

To reduce the chance of cuts, abrasions, or injuries, use sharp objects such as razors and nail clippers with caution, and avoid activities such as contact sports.

The elderly may be more sensitive to the side effects of this drug, especially abnormal bleeding/bruts, blood clots, swelling of the legs/ankles, muscle cramps, weakness, and loss of appetite.

Tell the doctor if you are pregnant or plan to become pregnant. Do not become pregnant while taking ponatinib. Lenatinib may harm an unborn baby. Before you start taking this medication, your doctor will perform a pregnancy test. managed access program Ask about reliable forms of birth control while taking this medication and within 3 weeks after stopping treatment. If you are pregnant, discuss the risks and benefits of this medication with your doctor immediately.

It is unclear whether this drug passes into breast milk. Because of the possible risk to the baby, it is not recommended to breastfeed while using this medicine and for 6 consecutive days after stopping the medicine.pharmaceutical consulting services Consult your doctor before breastfeeding.

ICLUSIG Side Effects

 Headache, dizziness, constipation or loss of appetite may occur. If these effects persist or worsen, tell your doctor or pharmacist immediately.

Remember, your doctor prescribes this medicine because he or she believes that the benefits to you outweigh the risks of side effects. Many people who use this drug do not have serious side effects.

If you have any serious side effects, Named Patient Supply please tell your doctor immediately, including: weight gain, skin numbness/tingling, pain/numbness/burning sensation in fingers/toes, fainting, fast/slow/slow/irregular/violent heartbeat, eye pain /Swelling/irritation, slow wound healing, sudden severe headache, blurred vision/vision problems, thinking problems.

Bonatinib sometimes causes side effects due to the rapid destruction of cancer cells (tumor lysis syndrome). To reduce the risk, your doctor may add medicine and tell you to drink plenty of water. Tell your doctor immediately if you have the following symptoms: lower back/side pain (back pain), signs of kidney problems (such as painful urination, pink/bloody urine, changes in urine output), muscle cramps/weakness.

If you have any very serious side effects, seek medical help immediately, including: abnormal bleeding/bruising, black/blood stools, vomit containing blood or coffee grounds, shortness of breath, seizures.

This medication may increase blood pressure. Check your blood pressure regularly and tell your doctor if the result is high. Your doctor may use medication to control blood pressure.

This medication may reduce your ability to fight infections. This may make you more susceptible to serious infections or worsen any of your infections. If there are any signs of infection (eg fever, chills, persistent sore throat, cough), please tell your doctor immediately.

For women of childbearing age, ponatinib may affect your fertility. Ask your doctor for more details.

Very severe allergic reactions to this drug are rare. named patient program india However, if you notice any symptoms of a severe allergic reaction, including skin rash, itching/swelling (especially face/tongue/throat), severe dizziness, and difficulty breathing, please seek medical help immediately.

This is not a complete list of possible side effects. If you notice other effects not listed above, please contact your doctor or pharmacist.

Iclusig

 uses

Panatinib is used to treat certain types of blood cancers (chronic myeloid leukemia-CML, acute lymphocytic leukemia-ALL). It works by slowing down or stopping the growth of cancer cells. It belongs to a class of drugs called kinase inhibitors.

How to use Iclusig

Please read the Medication Guide provided by your pharmacist before you start taking ponatinib and every time you supplement it. If you have any questions, please consult your doctor or pharmacist.

Follow your doctor's instructions to take this medication by mouth, with or without food, usually once a day. Swallow whole. Do not crush or dissolve this medicine. Unless your doctor instructs otherwise, drink plenty of water. The dosage depends on your medical condition, laboratory results, response to treatment, and other medications you may be taking. Be sure to inform your doctor and pharmacist of all products you use (including prescription drugs, over-the-counter drugs, and herbal products).

Do not increase the dose or take this medication more than the recommended dose. Your condition will not get better soon, and the risk of side effects will increase.

Use this medication regularly to get the most benefit. named patient basis, To help you remember, take it at the same time every day.

Unless your doctor or pharmacist says you can do this safely, you should avoid eating grapefruit or drinking grapefruit juice while using this medication. named patient program Grapefruit can increase the chance of side effects of this drug. Ask your doctor or pharmacist for more detailed information.

Acid-lowering drugs used for indigestion, heartburn, or ulcers (such as proton pump inhibitors/PPI, H2 blockers, antacids) may prevent ponatinib from working. If you are taking these drugs, please consult your doctor or pharmacist.

Since the drug can be absorbed through the skin and lungs and may harm an unborn baby, pregnant women or women who may become pregnant should not use the drug or inhale the dust in the tablet.

Lonsurf side effect

side effect

Important things to remember about the side effects of trifluoropyridine/tipexitate:

    Most people will not experience all the listed side effects of trifluoropyridine/tipixate.
    In terms of onset, duration and severity, the side effects of trifluridine/tipixate are usually predictable.
    After the treatment is completed, the side effects of trifluoropyridine/tipixate will improve.
    The side effects of Trifluridine/tipiricil may be easily controlled. There are many options to reduce or  prevent the side effects of trifluoropyridine/tipixate.

The following side effects are common in patients taking trifluoropyridine/tipixate (incidence rate is more than 30%):

•     fatigue
•     Low blood count.named patient program Your white and red blood cells and platelets may decrease temporarily. This can increase your risk of infection, anemia and/or bleeding.

•     weakness
•     nausea
•     Decreased appetite
•     diarrhea

These side effects are less common for patients receiving trifluoropyridine/tipixate:

•     Vomiting
•     stomach ache
•     fever

Not all side effects are listed above.Named Patient Supply Very rare side effects are not listed here-they occur in less than 10% of patients. However, if you experience any unusual symptoms, you should always tell your healthcare provider.